CTNM
Contineum Therapeutics Inc. - Ordinary Shares - Class A

141
Mkt Cap
$503.84M
Volume
228,111.00
52W High
$16.33
52W Low
$3.35
PE Ratio
-5.95
CTNM Fundamentals
Price
$13.00
Prev Close
$13.86
Open
$14.04
50D MA
$13.52
Beta
0.48
Avg. Volume
206,579.89
EPS (Annual)
-$2.17
P/B
1.86
Rev/Employee
$0.00
$61.97
Loading...
Loading...
News
all
press releases
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·1d ago
News Placeholder
More News
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $20.00 at Robert W. Baird
Robert W. Baird raised their price target on shares of Contineum Therapeutics from $14.00 to $20.00 and gave the stock an "outperform" rating in a research note on Friday...
MarketBeat·8d ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Posts Earnings Results, Beats Expectations By $0.01 EPS
Contineum Therapeutics (NASDAQ:CTNM - Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, topping the consensus...
MarketBeat·9d ago
News Placeholder
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·9d ago
News Placeholder
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·11d ago
News Placeholder
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus
Contineum Therapeutics surged 27% after a Zacks Rank upgrade, spotlighting how Zacks' strategies are beating a volatile market.
Zacks·12d ago
News Placeholder
Contineum Therapeutics (CTNM) Projected to Post Earnings on Thursday
Contineum Therapeutics (NASDAQ:CTNM) will be releasing its Q4 2025 earnings before the market opens on Thursday, March 5. (View Earnings Report at...
MarketBeat·17d ago
News Placeholder
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Rating of "Moderate Buy" by Analysts
Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the seven research firms that are currently covering the firm, Marketbeat...
MarketBeat·18d ago
News Placeholder
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·24d ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised shares of Contineum Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·29d ago
<
1
2
...
>

Latest CTNM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.